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A molecular clone of Japanese encephalitis (JE) virus Nakayama strain was used to create intertypic viruses containing either the 5′-C-prM-E
or the prM-E region of the attenuated JE SA14-14-2 virus in the JE Nakayama background. These two intertypic JE viruses, JE-X/5′CprME(S) and
JE-X/prME(S), respectively, generally resembled the parental JE virus in cell culture properties. Similar to virus derived from the JE Nakayama
molecular clone (JE-XJN), JE-X/prME(S) was highly neuroinvasive and neurovirulent for young adult mice, whereas JE-X/5′CprME(S) was
attenuated for neuroinvasiveness and only partially attenuated for neurovirulence. Immunization of young mice with JE-X/5′CprME(S) virus
elicited neutralizing antibodies against JE Nakayama virus and conferred protection against encephalitis following challenge with JE Nakayama
virus. The sequence of the JE-X/5′CprME(S) virus differed from that of JE-X/prME(S) virus at two nucleotides in the 5′ UTR, 3 amino acid
positions in the capsid protein, 4 positions in the prM protein and 1 in the envelope protein. For JE-X/prME(S) virus, the 4 differences in prM and
the single substitution in the envelope represented reversions to the sequence of JE Nakayama virus. Overall, this study reveals that molecular
determinants associated with the prM-E region of the attenuated JE SA14-14-2 virus are insufficient by themselves to confer an attenuation
phenotype upon JE Nakayama virus. This suggests a role for determinants in the 5′ UTR and/or the capsid protein of the JE SA 14-14-2 virus
genome in influencing the virulence properties of the JE Nakayama virus in the mouse model.
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Japanese encephalitis (JE) virus is the principal member of the
JE serogroup, which includes several agents of acute neurologic
disease in humans (Monath and Heinz, 1996). JE is the most
important cause of arthropod-transmitted acute viral encephalitis
on a worldwide basis (Tsai, 1994). The virus causes seasonal
epidemic outbreaks and sporadic endemic disease in many
countries of Western and Southeast Asia (Burke and Leake,
1988; Halstead and Jacobson, 2003). It is estimated that as many
as 30,000 cases of acute encephalitis due to JE virus occur
annually within the Peoples Republic of China alone. Moreover,
the geographic distribution of the virus has changed in recent
years, with extension of its westward range into provinces of
India and southward into Indonesian islands adjacent to Australia⁎ Corresponding author. Fax: +1 267 305 6407.
E-mail address: thomas_chambers2@merck.com (T.J. Chambers).
0042-6822/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2007.04.016(Mackenzie et al., 2004). Neurologic disease caused by JE is
often serious, with a mortality rate as high as 30%, and permanent
neurological sequellae are frequently observed among survivors
(Solomon et al., 2000). Traditionally, vaccine products for
prevention of JE have included inactivated virus prepared from
mouse-brain, and the live-attenuated JE SA14-14-2 strain, which
is not licensed for use outside of China (Tsai, 1994). Second
generation vaccines for worldwide use are needed, primarily
because of adverse reactions associated with mouse-brain-
derived vaccines (Marfin et al., 2005; Takahashi et al., 2000).
Various approaches have been taken to investigate the
molecular basis of JE virus virulence, including comparisons of
nucleotide sequences of virus strains differing in virulence pro-
perties, and of engineered viruses as well as mutants selected for
neutralization resistance or receptor escape. Mutations in the
envelope protein have generally been regarded as critical in
governing the attenuation of JE virus in mouse model systems
(Cecilia and Gould, 1991; Hasegawa et al., 1992; Ni et al.,
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1998). Molecular characterization of the JE SA14-14-2 vaccine
and related attenuated strains suggests that there are multiple
attenuating determinants within the E proteins relative to their
parental JE SA14 viruses (Nitayaphan et al., 1990; Aihara et al.,
1991; Ni et al., 1994, 1995). To further evaluate this hypothesis,
we tested whether the structural proteins of the JE SA14-14-2
strain would attenuate neuroinvasiveness and neurovirulence of
the virulent JE Nakayama virus in the mouse model. This was
done by constructing and testing intertypic structural region JE
viruses. One such virus, containing the 5′ UTR, C, prM and E
regions from JE SA14-14-2 virus, exhibited an attenuated
phenotype in this model and was shown to have efficacy as an
experimental vaccine.
Results
Recovery of JE-X/5′CprME(S) and JE-X/prME(S) viruses
Fig. 1 indicates the genomic organization of the viruses used
in this study. JE-XJN represents the parental JE Nakayama virus
infectious clone. For JE-X/prME(S), the 5′ terminus through the
capsid protein region was derived from the JE-XJN clone,
whereas the prM and E regions were derived from the JE SA14-
14-2 virus. For JE-X/5′CprME(S), the 5′ terminus through the E
region was derived from the JE SA14-14-2 virus. For both
intertypic viruses, the region from NS1 through the 3′ UTR was
derived from the JE-XJN clone. Thus, the two intertypic viruses
were designed to differ only with respect to the region encoded
from the 5′ terminus through the capsid protein.
Yields of infectious JE-XJN virus after transfection were in
the range of 3×107 to 1×108 PFU/ml. The plaque size was
identical to that of parental JE Nakayama virus (approximately
3 to 4 mm after 4 to 5 days of incubation). Transfection harvests
of the two intertypic viruses yielded concentrations on the
order of 5.5×106 to 7.5×106 PFU/ml. The JE-X/prME(S) virus
formed plaques on Vero cell monolayers that resembled those
of the parental JE-XJN clone. The JE-X/5′CprME(S) virusFig. 1. Structure of the JE-XJN and intertypic viruses. At top is shown the
parental JE-XJN virus molecular clone. Below are engineered viruses containing
JE SA14-14-2 structural proteins. Open regions depict the regions of the JE
SA14-14-2 virus incorporated into the JE-XJN molecular clone, as also
indicated by arrows below the diagrams. For clarity, the nonstructural regions of
the chimeras are not drawn to scale.formed plaques of 2–3 mm that were less distinct and required
1–2 days longer to form than those of JE-XJN virus.
Nucleotide sequence analysis
The nucleotide sequence of the JE-XJN virus was described
previously, and is homologous to other virulent JE virus strains
(Chambers et al., 2006). For the JE-X/5′CprME(S) and JE-X/
prME(S) viruses, the nucleotide sequences from the 5′ terminus
through E regionswere determined for the plasmid templates used
for generation of infectiousRNA transcripts, and also from cDNA
derived by RT/PCR of virus-infected Vero cell monolayers, using
the same virus stocks employed for the cell culture and mouse
experiments. Table 1 indicates the results. Comparison is made
with the virulent JE-XJN virus, and the attenuated JE SA14-14-2
virus (Nitayaphan et al., 1990). In the case of both intertypic
viruses, a few unexpected differences were observed between the
plasmid templates and the recovered viruses, resulting in some
differences in their prM and E proteins, as described below.
JE-X/5′CprME(S) differed unexpectedly from JE SA14-14-
2 virus at 1 nucleotide in the 5′ UTR (u instead of g at position
26), and 1 amino acid in the capsid region (serine instead of
glycine at position 40), both of which emerged after recovery of
JE-X/5′CprME(S) virus from its plasmid template. JE-X/5′
CprME(S) differed from JE-XJN virus at two nucleotide subs-
titutions in the 5′ UTR (u instead of g at position 26 and a
instead of u at position 39), as well as 3 amino acid substitutions
in the capsid, 4 in the prM region, and 13 in the E protein. JE-X/
5′CprME(S) differed from JE-X/prME(S) virus at the two nuc-
leotide positions in the 5′ UTR mentioned above, at 3 amino
acids in the capsid protein (residues 40, 66, and 100), at 2 amino
acids in the prM protein (residues 14 and 16, where reversion of
JE-X/prME(S) sequence to that of JE-XJN occurred), and at 1
amino acid in the E protein (residue 315). At two positions in
the prM protein, the JE-X/prME(S) virus contained a mixture of
residues found in both JE-X/5′CprME(S) and JE-XJN viruses.
JE-X/prME(S) differed from JE-XJN virus at the two 2
amino acid positions in the prM region where mixed residues
were found, and at 12 amino acids in the E region. The lack of
complete similarity in the nucleotide and amino acid sequences
of the intertypic viruses was therefore due to clonal substitutions
in the 5′UTR and capsid protein of JE-X/5′CprME(S) virus and
reversions in the prM and E proteins of JE-X/prME(S) virus
(see Discussion).
Additional nucleotide sequencing of a 2500-bp region from
the carboxy-terminus through the 3′ UTR was conducted to
determine if the intertypic viruses harbored a high level of
substitutions as a result of possible genetic incompatibilities
between JE SA14-14-2 and JE-XJN virus. Results are included
in the Supplementary Material. Each virus contained only a few
silent nucleotide substitutions and a single unique amino acid
substitution.
Growth properties of the JE viruses
The growth kinetics of the JE-XJN virus and the parental JE
Nakayama virus from which it was derived are compared in Fig.
Table 1
Comparison of JE virus sequences a
Position JE SA14-14-2 b JE-X/5′CprME(S) JE-X/prME(S) JE-XJN
5′UTR-26 g u (g) – –
5′UTR-39 a – u u
C40 G S (G) – –
C66 S – L L
C100 R – G G
prM14 I – V (I) V
prM16 N – K (N) K
prM129 I – I, V c (V) V
prM140 V – I, V d (I) I
E91 S – – V
E107 F – – L
E138 K – – E
E176 V – – I
E177 A – – T
E227 S – – P
E242 F – – E
E244 G – – E
E264 H – – G
E279 M – – K
E315 V – A (V) A
E345 L – – P
E439 R – – K
a Dashed lines indicate the same nucleotide or amino acid as in JE SA14-14-2.
Substitutions in parentheses indicate nucleotides and amino acids observed in
plasmid templates.
b Nitayaphan et al. (1990).
c Sequence data indicate mixed residues at this position.
d Sequence data indicate mixed residues at this position.
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occurred at 48 h and was 7.25 log PFU/ml. The peak titer of JE-
XJN virus in LLC-MK2 cells occurred at 60 h and was
8.5 log PFU/ml. In C6/36 cells, JE Nakayama virus was slightly
more rapid in initial virus production over the initial 36 h, but
reached a peak titer at 60 h which was similar to that of JE-XJN,
approximately 7.5 logs.
Virus production for the two intertypic viruses was compared
to that of JE Nakayama virus in LLC-MK2 and C6/36 cells
(Figs. 2C and D). JE Nakayama was used in these experiments
because no major differences in growth properties were found
between it and JE-XJN in these cell lines. In LLC-MK2 cells,
JE Nakayama virus reached a peak titer of approximately
7.0 logs. The JE-X/prME(S) virus exhibited very similar kine-
tics of virus production with the same peak titer. In contrast, the
JE-X/5′CprME(S) virus exhibited reduced virus production at
early time points, but eventually reached a peak titer similar to
those of the other viruses. In C6/36 cells, JE Nakayama virus
reached a peak titer of approximately 9.0 logs. The JE-X/prME
(S) virus initially displayed a similar rate of virus production,
but reached a titer of only 8.0 logs at the conclusion of the
experiment. JE-X/5′CprME(S) virus was reduced in initial rate
of virus production, and eventually reached a peak titer of only
6.75 logs.
Mouse virulence testing
The virulence properties of the parental and the intertypic JE
viruses were evaluated by intracerebral (i.c.) and intraperitoneal(i.p.) inoculation of weaned (3- to 4-week-old) ICR mice. In an
initial pilot experiment to evaluate the neurovirulence of the JE
Nakayama and JE-XJN viruses, 4-week-old mice were
inoculated with a dose of 4.0 logs PFU of either virus by the
i.c. route. 100% mortality was observed for these two viruses
and average survival times were similar (9 days for each virus).
In a separate preliminary experiment to evaluate the neuroviru-
lence of the intertypic viruses, i.c. inoculation of 4-week-old
ICR mice with fixed doses was also tested. At a dose of 6.1 logs,
12 of 12 mice inoculated with the JE-X/prME(S) virus suc-
cumbed to infection. In contrast, at a dose of 5.6 logs only 7/12
mice inoculated with the JE-X/5′CprME(S) succumbed to in-
fection. Average survival times for these groups of mice were
5.6 and 7.6 days, respectively (data not shown).
Further evaluation of the neurovirulence properties of the
JE-XJN and intertypic viruses was done by dose titration
experiments using the same mouse model as for the pilot
experiments. Table 2 shows the results of these experiments.
The JE-XJN virus exhibited less than 100% mortality when the
dose was lowered below 1.0 log, and the LD50 was 0.50 PFU.
JE-X/prME(S) virus was tested in three independent experi-
ments (shown in Table 2). In one experiment, the calculated
LD50 was 0.20 PFU. In 2 of the 3 experiments, the data did not
allow calculation of the LD50. In contrast to both JE-XJN and
JE-X/prME(S) viruses, the JE-X/5′CprME(S) virus exhibited
less neurovirulence, based on less than 100% mortality at or
below a dose of 4 log. The LD50 was 1.40 PFU. At two of four
comparable doses where JE-X/5′CprME(S) and JE-X/prME(S)
were tested in the same LD50 experiment, the mortality
percentages were significantly different (p=0.023 at 0.8 vs.
0.9 log PFU [JE-X/5′CprME(S) vs. JE-X/prME(S), respec-
tively]; p=0.023 at 5 vs. 4 log PFU [JE-X/5′CprME(S) vs.
JE-X/prME(S), respectively]). Average survival times in these
experiments ranged from 5 to 12 days among the different
doses tested, with longer survival times observed at the lower
doses.
In initial experiments to evaluate the neuroinvasiveness of
the JE Nakayama and JE-XJN viruses, 3-week-old mice were
inoculated with a dose of 4.7 logs PFU by the intraperitoneal
route (Table 3). Mortality percentages were similar for the two
viruses (60% for JE-XJN and 50% for JE Nakayama virus,
respectively). Average survival times were 5 days in both cases.
Neuroinvasiveness of the two intertypic viruses was initially
evaluated by inoculation of 3-week-old mice with doses of
approximately 6 logs PFU by the i.p. route. The mortality for
mice inoculated with JE-X/prME(S) was 70%, with an average
survival time of 6.3 days. In contrast, the mortality rate for mice
inoculated with the JE-X/5′CprME(S) was 0%, and no mice
exhibited signs of illness.
Since the JE-X/prME(S) virus exhibited neuroinvasiveness,
further studies were done to characterize this property. Dose
titration studies were conducted using the parental JE-XJN virus
and JE Nakayama viruses as controls (Table 3). At doses in the
range of 2.5 to 4.4 log PFU, all mice inoculated with JE-XJN
had similar levels of mortality ranging from 28% to 50%. The
JE Nakayama virus exhibited generally similar mortality
percentages over the same dose range (40–66%). In the same
Fig. 2. Growth curve analysis of the JE-XJN, and intertypic JE viruses. Infections were done as described in Materials and methods. (A, B) Results for parental JE
Nakayama (open symbols) and JE-XJN (closed symbols) viruses on LLC-MK2 and C6/36 cells, respectively. (C, D) Results for JE Nakayama (open squares), JE-X/
prME(S) (closed circles) and JE-X/5′CprME(S) (open diamonds) viruses on LLC-MK2 and C6/36 cells, respectively. Values represent the mean±standard deviation
(SD) for three independent samples harvested and tested for each time point. In most cases, SD values were small and error bars are not visible.
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roinvasiveness at doses of 4.6 and 5.5 log PFU, with mortality
rates of 28% to 42.8%, respectively. LD50 values could not be
calculated for any group due to incomplete mortality even at the
highest doses tested.
Immunogenicity of intertypic viruses
To determine what levels of neutralizing antibodies against
JE Nakayama virus were produced after immunization with theTable 2
Neurovirulence testing a
Virus Dose range b LD50 Average survival
times (days) c
JE-XJN 0.3–1.9 0.50 5.4–8.6
JE-X/prME(S) d 2.3–5.4 NA 5.9–6.4
JE-X/prME(S) d 0.3–3.5 b0.3 5.2–6.0
JE-X/prME(S) d 0.1–3.6 0.20 6.0–9.5
JE-X/5′CprME(S) 0.8–5 1.40 7.0–12
a Intracerebral inoculation; groups of 5–7 mice per dose.
b Log PFU/dose.
c Range of average survival times among different dose groups.
d Three independent experiments with JE-X/prME(S) virus were performed.intertypic viruses, sera obtained from mice which had been
inoculated by the i.p. route with either JE-X/prM-E(S) or JE-X/
5′CprME(S) from Experiment 2 shown in Table 3. Table 4
shows the results of plaque-reduction titers using 50% end-
points. Both viruses elicited neutralizing antibodies, with titers
ranging from 320 to 2560 (GMT of 910) for JE-X/5′CprME(S),
and a titer of 1280 (GMT of 1280) for JE-X/prME(S), respec-
tively. Only the three mice which survived inoculation with JE-
X/prME(S) virus were tested for neutralizing antibodies in this
experiment. There was no significant difference in the GMTs of
the samples. A true comparison of the maximal antibody res-
ponses generated by these two viruses is not available, as only a
single time point was measured in these experiments.
Protective immunity induced by JE-X/5′CprME(S) virus
Because the JE-X/5′CprME(S) virus was attenuated for
neuroinvasiveness and induced neutralizing antibodies against
JE Nakayama virus, it was evaluated for the capacity to generate
protective immunity against challenge with this virus. C57BL/6
mice were mock-immunized or immunized at 5 weeks of age
with 6.1 log PFU of JE-X/5′CprME(S) virus, and then chal-
lenged at 14 weeks of age with 20,000 PFU of JE-XJN virus by
Fig. 3. Protection of C57BL/6 mice against JE virus encephalitis after
immunization with the JE-X/5′CprME(S) virus. Mice were mock-immunized
or immunized with JE-X/5′CprME(S) virus and challenged with JE Nakayama
virus by the i.c. route and observed until moribund or sacrificed as described in
the text. Statistical comparisons for mortality rates and average survival time
were significant, as described in the text.
Table 3
Neuroinvasiveness of JE viruses a
Virus Dose b Mortality %
Experiment 1
JE-XJN 4.7 6/10 60
JE-Nakayama 4.7 5/10 50
Experiment 2 c
JE-X/prME(S) 6.0 7/10 70
JE-X/5′CprME(S) 5.6 0/10 0
Experiment 3
JE-XJN 4.4 2/7 28.6
4.3 3/6 50
3.2 2/5 40
2.5 2/7 28.6
JE-Nakayama 4.5 2/5 40
3.7 4/6 66
2.7 4/8 50
JE-X/prME(S) 5.5 2/7 28.6
4.6 3/7 42.8
a Intraperitoneal inoculation of 4-week-old ICR mice.
b Log PFU/dose.
c p=0.003 for difference in mortality percentage.
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cumbed to infection with typical signs of acute encephalitis, and
the average survival time was 5.9 days (range 5 to 8 days). In
contrast, only 2/12 mice immunized with JE-X/5′CprME(S)
virus developed a lethal infection and survived for 8 and 10 days,
respectively. The difference in the mortality percentages and
average survival times were significant between the mock-
immunized and immunized groups (pb0.001 and p=0.02,
respectively).
Brains of some of the mock-immunized and immunized mice
were recovered on post-challenge day 5 to determine if there
were differences in the amounts of brain-associated virus. Brains
of 4 mock-immunized mice contained a mean of 10.44
(±1.2 logs PFU/g) of brain tissue at a time when these mice
appeared moribund. Brains of 3 mice immunized with JE-X/5′
CprME(S) virus contained a mean of 7.15 (±1.2 logs PFU/g),
and these mice exhibited no signs of illness at this time.
These latter mice were not used for calculations of the mortality
percentages.
To evaluate the magnitude of change in circulating neutra-
lizing antibody titers associated with protection from ence-Table 4
Plaque-reduction neutralization titers a
Sample Day b N GMT Range
Immunization
JE-X/5′CprME(S) 38 6 910 c 320–2560
JE-X/prME(S) 38 3 1280 c 1280
Immunization and challenge
Mock-immunized/Challenged 5 4 80
d
40–160
Immunized/Challenged 5 3 3175 d, e 2500–5120
Immunized/Challenged-4 21 5 6756 e 2560–10240
a 50% plaque reduction titers, as reciprocal of serum dilution.
b Day serum obtained post-immunization or post-challenge.
c p=0.45.
d pb0.001.
e p=0.11.phalitis after the immunization and challenge, post-challenge
titers were measured in both surviving immunized mice and
moribund mock-immunized mice harvested on day 5 of the
experiment (Table 4). Mock-immunized mice which suc-
cumbed by day 5 post-challenge exhibited titers in the range of
40–160 (GMT of 80). Among the three immunized mice
sacrificed at day 5, the titer at this time was already 37-fold
higher (GMT of 3175). Among mice which survived chal-
lenge, the level had increased to a GMT of 6756 by day 21
post-challenge. Although a control of immunized and
nonchallenged mice was not tested, the large increase in titers
of immunized mice indicates a substantial anamnestic response
occurs in those immunized mice which survived challenge.
Discussion
In this study, a JE Nakayama molecular clone, referred to as
JE-XJN, was used as the basis for constructing two intertypic
JE viruses, JE-X/5′CprME(S) and JE-X/prME(S). These
expressed either the 5′ UTR, capsid, prM and E regions, or
only the prM and E regions, respectively, of the attenuated JE
SA14-14-2 virus, in the JE Nakayama background. The
intertypic viruses exhibited cell culture properties that were
generally similar to those of the parental JE viruses, including
virus production in cell lines of mammalian and mosquito
origin, and plaque formation on Vero cells. Overall, the results
indicate no severe defect in virus replication resulting from
replacement of the prM and E proteins of JE Nakayama virus
with those of JE SA14-14-2. However, inclusion of the 5′
UTR and capsid region from the JE SA14-14-2 virus did cause
some deleterious effects on virus production in cell culture.
JE Nakayama virus is a virulent strain of JE virus, charac-
terized by high neuroinvasiveness and high neurovirulence for
mice (Cao et al., 1995; Ni and Barrett, 1996; Lee and Lobigs,
2002). As demonstrated in weaned mice, the JE-XJN virus and
its parental JE Nakayama virus exhibited neuroinvasive and
neurovirulent phenotypes. However, uniform neuroinvasive-
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This likely results from these viruses being maintained as cell
culture-passaged virus stocks rather than as suckling mouse
brain suspension, which retains higher neuroinvasiveness for
mice of this age (Lee and Lobigs, 2002).
JE SA14-14-2 is a highly attenuated strain of JE virus, cha-
racterized by lack of both neuroinvasiveness and intracerebral
neurovirulence in weanling mice (Eckels et al., 1988). Intro-
duction of the prM and E proteins of the JE SA14-14-2 virus
into the JE Nakayama background was predicted to result in
attenuation of the virulence properties of the latter virus. This
expectation is based on the fact that the E protein harbors critical
determinants of virulence for JE virus, as shown for several
different strains of JE virus (Sumiyoshi et al., 1995; Cecilia and
Gould, 1991; Hasegawa et al., 1992; Ni and Barrett, 1998).
Virulence testing of the JE-X/prME(S) virus in 3- to 4-week-old
mice revealed it to be neurovirulent and neuroinvasive, with
overall properties generally similar to those of the JE-XJN virus.
In contrast, the JE-X/5′CprME(S) virus was less virulent than
JE-XJN and JE-X/prME(S), with no evidence of neuroinva-
siveness or signs of illness among mice inoculated intraper-
itoneally with doses as high as 5.6 logs PFU, and incomplete
mortality at doses as high as 4 logs PFU given intracerebrally.
Although we did not test the JE SA14-14-2 virus in these
experiments, comparison of the JE-X/prME(S) and JE-X/5′
CprME(S) viruses for mortality percentages revealed differ-
ences in both neurovirulence (Table 2) and neuroinvasiveness
(Table 3), indicating a relative attenuation phenotype of the JE-
X/5′CprME(S) virus. However, based on available data for JE
SA14-14-2 (Eckels et al., 1988), JE-X/5′CprME(S) virus is only
partially attenuated with respect to neurovirulence. We therefore
conclude that the prM and E proteins of the JE SA14-14-2 virus
are not capable of fully attenuating the virulence properties of
the JE Nakayama virus. Rather, the 5′ UTR and capsid protein
regions of JE SA14-14-2 virus are required to attenuate neu-
roinvasiveness, but only partially attenuate neurovirulence.
These observations do not mean that the E protein of the JE
SA14-14-2 virus lacks attenuating determinants for the virulent
JE-SA14 virus from which it was derived. In this regard, JE
SA14 virus is quantitatively less virulent in the mouse model
than JE Nakayama virus (Cao et al., 1995; Ni and Barrett,
1996), so attenuating determinants within the JE SA14-14-2
virus E protein alone may be sufficient to eliminate neuroinva-
siveness and reduce neurovirulence of the JE SA14 strain.
In other experimental systems where chimeric flaviviruses
have been used to test effects of structural proteins from atte-
nuated viruses, the prM and E proteins have often been ob-
served to confer strong attenuating effects. For instance, the
prM and E proteins of the highly attenuated dengue-2 strain
were sufficient to abolish the neuroinvasiveness and lower the
neurovirulence of JE Nakayama virus (Chambers et al., 2006).
Similar results were observed with a corresponding JE/dengue-
4 chimeric virus (Mathenge et al., 2004). In the context of a
chimeric yellow fever/JE virus, the prM and E proteins of JE
SA14-14-2 profoundly attenuated the neurovirulence of the
yellow fever 17D strain, even at doses as high as 106 PFU
delivered intracerebrally (Chambers et al., 1999). In the case ofthe JE-X/prME(S) virus, the prM and E proteins of JE SA14-14-
2 virus may not be able to overcome an intrinsically high level
of virulence contributed by the remainder of JE Nakayama virus
genome.
Genetic differences between the JE-X/5′CprME(S) and JE-
X/prME(S) viruses in the region from the 5′ UTR through the E
protein included multiple nucleotide and amino acid substitu-
tions that presumably contribute to differences in their virulence
properties. For the 5′UTR, insight into the possible significance
of the differences was sought by generating secondary structure
models for the two viruses (Fig. 4). The structures formed for
the parental JE-XJN and the two intertypic viruses resemble the
most stable predictions for the 5′ UTR of flaviviruses,
consistent with those modelled for JE, dengue and other viruses
(Brinton and Dispoto, 1988; Cahour et al., 1995; Thurner et al.,
2004). For JE-XJN and JE-X/prME(S), nucleotides 26 and 39
are contained within a small bulge at the end of the long stem
formed by nucleotides 20 to 45. In contrast, the 5′UTR of JE-X/
5′CprME(S) lacks this bulge because the uridine substitution at
position 26 compensates for the adenine at position 39, to create
a longer stem structure. The JE SA14-14-2 virus contains an
adenine nucleotide at position 39, but a guanosine at position
26, resulting in a bulge slightly smaller than that observed for
the JE-XJN virus, indicating that this feature is not specific to
the virulent JE strains. The lack of any major effect of the
substitutions in the 5′ UTRs on predicted RNA structure, and
the presence of similar structures for JE SA14-14-2 and JE-XJN
viruses suggests that these substitutions may not affect the
functional properties of the 5′ UTR. Ni et al. have analyzed the
5′ UTR sequences of multiple JE viruses in the lineage of the JE
SA14-14-2 vaccine strain from its JE SA14 precursor (Ni et al.,
1994), and concluded that the adenine substitution at position
39 is not a marker for JE virus virulence. Furthermore, positions
26 and 39 lie within a region of the 5′ UTR structure that has
been found non-essential for viral replication or mosquito com-
petence in the context of dengue-4 virus (Cahour et al., 1995).
Amino acid substitutions were observed between JE-X/
prME(S) and JE-X/5′CprME(S) viruses in the capsid, prM and
E protein regions. One or more of these substitutions could
affect steps in polyprotein processing, RNA synthesis, and/or
virus assembly, and contribute to the moderate defect in virus
production in LLC-MK2 cells observed with the JE-X/5′CprME
(S) virus. A corresponding or even worse degree of impairment
of replication efficiency of this virus in mouse tissues could
explain its lack of neuroinvasiveness, based on a low virus
burden being generated in peripheral tissues prior to induction
of an immune response capable of controlling the infection. The
lower neurovirulence of JE-X/5′CprME(S) virus, as reflected
by an LD50 7.5-fold higher than that of the JE-X/prME(S) virus
after intracerebral inoculation, is consistent with this hypoth-
esis, as rate of virus production in the central nervous system is
a marker for virulence of flaviviruses (Schlesinger et al., 1996).
The three amino acid substitutions in the capsid protein
where JE-X/5′CprME(S) differed from JE-X/prME(S) virus do
not occur in regions of conserved RNA sequences (Markoff,
2003), and therefore effects on RNA structure were not mo-
delled. To gain insight into possible effects of the substitutions
Fig. 4. Modelled RNA structures for the 5′ UTR of the parental JE-XJN and JE-X/prME(S) viruses (left) and the JE-X/5′CprME(S) virus (middle), and JE SA14-14-2
virus (right). Positions of the nucleotide substitutions 29 and 36 are indicated. Modelling procedures were as described in Materials and methods.
57T.J. Chambers et al. / Virology 366 (2007) 51–61at positions 40 and 66, a homology model for the JE virus
capsid was derived based on the structure for the dengue-2 virus
(Ma et al., 2004). Relative positions of the substitutions found in
the JE-X/5′CprME(S) capsid are shown in Fig. 5. Modelling of
the predicted local effects of the substitutions at positions 40
and 66 of the JE virus capsid is discussed in Supplementary
Information. Position 40 lies within the loop connecting the
alpha 1 and alpha 2 segments, whereas position 66 lies withinFig. 5. Homology model for the JE Nakayama capsid protein, based on the dengue-
Capsid monomers are shown in green and magenta, respectively. Positions of residuthe helical alpha 3 segment. Based on the solution structure for
dengue-2 virus (Ma et al., 2004), both of these substitutions lie
within regions that are involved in stabilization of the capsid
monomer core, and in formation of the hydrophobic cleft that
serves to associate the capsid with intracellular membranes. In
the case of the JE-X/5′CprME(S), the two serine substitutions
may result in deleterious effects on the function of the capsid
protein dimer due to loss of hydrophobic character in this region2 structure. Modelling procedures were as described in Materials and methods.
es 40 and 66 are indicated.
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that deletions encompassing this region of the capsid protein
reduce the virulence of TBEV for mice, probably through des-
tabilization of the capsid dimers and their interaction with
membrane surfaces (Kofler et al., 2002, 2003). The possible
effects of the substitution at position 100 were not analyzed,
since this position does not lie within the model.
Two amino acid substitutions in the pr region (positions 14
and 16) differentiated the JE-X/5′CprME(S) and JE-X/prME(S)
viruses. These were unexpected reversions to residues found in
the parental JE-XJN virus. Selective pressure for reversion also
occurred at positions 129 and 140 in the prM region of JE-X/
prME(S) virus, where mixtures of valine and isoleucine were
observed. These partial and complete reversions were pre-
sumably selected during transfection and amplification of JE-X/
prME(S) virus on Vero cells, and may reflect a requirement for
replicative fitness of the virus in the context of the intertypic
capsid/prM-E region. None of these positions in the prM region
have been classified as virulence determinants for JE viruses
(Nitayaphan et al., 1990; Aihara et al., 1991; Ni et al., 1995).
With regard to attenuating determinants in the JE virus E
protein, JE SA14-14-2 contains multiple substitutions com-
pared to its parental JE SA14 strain (Nitayaphan et al., 1991).
However, comparison of various attenuated derivatives of JE
SA14 viruses, including JE SA14-14-2, JE SA14-5-2 and JE
SA14-2-8, has revealed a consensus of four common amino
acid substitutions (E-138, E-176, E-315, and E-439) that are
associated with attenuation (Nitayaphan et al., 1990; Aihara et
al., 1991; Ni et al., 1995). All four substitutions were found in
the E protein of JE-X/5′CprME(S) and all but position 315 were
found in the E protein of JE-X/prME(S) virus. Eight additional
substitutions specific to the JE SA14-14-2 virus (positions E-91,
E-107, E-177, E-227, E-244, E-264, E-279, and E-345) were
also found in both intertypic viruses. Of particular note,
substitution of lysine for glutamate at position 138, which
was reported as a strongly attenuating determinant for the JE
JaOArS982 strain (Sumiyoshi et al., 1995; Zhao et al., 2005),
was not sufficient to attenuate the JE-XJN virus in our expe-
riments. Potential virulence determinants in the nonstructural
region and/or the 3′ UTR of JE-XJN virus might negate or
counteract effects of position 138 or other attenuating sites in
the E protein and account for the lack of attenuation of JE-X/
prME(S) virus.
One amino acid substitution in the E protein (position 315)
differentiated the JE-X/5′CprME(S) and JE-X/prME(S) viruses,
where reversion to the residue found in JE-XJN virus was un-
expectedly found in the latter virus. Although the alanine subs-
titution is found among virulent strains of JE virus (Ni et al.,
1995), there are some experimental evidence that it does not
exert any dominant effect on virulence properties associated
with the JE virus E protein (Arroyo et al., 2001).
Because of the attenuated properties of JE-X/5′CprME(S)
virus, experiments were done to evaluate its potential as an
experimental vaccine. Neutralizing antibody responses elicited
against JE Nakayama virus after peripheral inoculation of
young mice were comparable to those induced by the neuro-
invasive JE-X/prME(S) virus. Weanling mice are highly sus-ceptible to intracerebral inoculation with the JE Nakayama
virus, and challenge with this strain serves as a severe test of a
protective immune responses. Using this model, 100% mor-
tality was found in mock-immunized mice, whereas immuniza-
tion with JE-X/5′CprME(S) virus was able to protect 83%
percent of mice, indicating a high degree of efficacy as a
prophylactic vaccine. The post-challenge antibody responses in
immunized mice were 6- to 20-fold higher than those of mock-
immunized mice by day 5 post-challenge and continued to rise
another 2- to 3-fold by 3 weeks post-challenge. This anamnestic
response was associated with a reduction of brain-associated JE
Nakayama challenge virus as early as 5 days post challenge,
compared to levels found in mock-immunized mice. Lack of
complete protection of immunized mice against challenge with
JE Nakayama virus is presumably related to variability in the
levels of neutralizing antibody produced in response to immu-
nization with JE-X/5′CprME(S) virus (Table 4). For instance,
the magnitude of the anamnestic response has been identified as
a critical factor in the control of JE virus encephalitis in the
mouse model (Konishi et al., 1999).
JE virus causes an acute encephalitis in humans that is
preventable using vaccination with live-attenuated JE virus [JE
SA14-14-2 (Chinese vaccine strain; Eckels et al., 1988)] or with
inactivated vaccine (JE-VAX; Tsai, 1994). The attenuation phe-
notype of the live-attenuated JE SA14-14-2 vaccine is presumed
to involve numerous mutations which occurred during passage
in PDK (primary dog kidney cells), and which differentiate it
from its JE SA-14 parent and other virulent JE virus strains
(Nitayaphan et al., 1990; Ni et al., 1994, 1995). However, the
molecular basis of attenuation of JE SA-14 virus has not been
fully defined. The results of our study suggest that the 5′ UTR
and capsid regions of the JE SA14-14-2 virus may contain
attenuating mutations, but their importance may depend on the
genetic background of the JE virus strain. Mutations in the prM
and E proteins may be sufficient for attenuation of JE SA14
virus, although further studies are required to confirm this
hypothesis. Such studies may yield information that can be used
for engineering of novel live-attenuated viral vaccines for JE
virus.
Materials and methods
Cells and viruses
Vero and C6/36 cells were originally obtained from the
American Type Culture Collection (ATCC) and maintained in
alpha minimal essential media (alpha-MEM) plus 10% fetal
bovine serum. LLC-MK2 cells (ATCC) were maintained in M-
199media plus 20% fetal bovine serum (FBS). The JE SA14-14-
2 virus was previously described (Chambers et al., 1999). The JE
Nakayama virus clone (JE-XJN) was described previously
(Chambers et al., 2006). Plaque assays for JE viruses were done
in confluent Vero cells, using an overlay of 1% ME agarose
(Biowhittaker), in alpha MEM plus 5% FBS and incubated at
37 °C for 4 to 5 days. Plaques were visualized by staining with
0.05% neutral red in phosphate-buffered saline, followed by
fixation in 7% formalin and staining with 1% crystal violet.
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The JE-XJN molecular clone utilizes two plasmids (pJE5′
NB25 and pCR-XL3′BK2), encoding the 5′ 3.4 kb and the 3′
7.5 kb of the JE Nakayama virus genome, to generate infectious
JE virus (Chambers et al., 2006). The plasmid pJE5′NB25 was
therefore used for construction of intertypic JE viruses con-
taining the 5′ UTR, and/or the C, prM and E proteins of JE
SA14-14-2 virus in the JE-XJN background.
JE SA14-14-2 virus RNA was obtained from virus-infected
LLC-MK2 cells using Trizol LE reagent (Gibco/BRL). The final
RNA pellet was dissolved in RNAse-free water. The primers for
the reverse transcription and long polymerase chain reaction
amplification were as follows (5′ to 3′). Sense primers are in-
dicated by (+), and antisense by (−).
JE5′(+): 5′-AGAAGTTTATCTGTGTGAACTTCTT-3′
JE(E/NS1)(−): 5′-CACATCCAGTGTCAGCATGCACAT-
TG-3′
These primers were based on the JE-SA14 sequence (Nita-
yaphan et al., 1990). cDNA synthesis was done using Super-
script II RNAseH(−) reverse transcriptase (Gibco/BRL). 1–2 μg
of JE virus RNAwas mixed with 10 pmol of JE(E/NS1) primer,
heated for 10 min at 70 °C, cooled on ice, and then incubated
with Superscript II in the appropriate buffer for 2–4 h at 42 °C.
Reactions were then treated with DNAse-free ribonuclease H at
37 °C for 20 min, followed by heating to 70 °C for 10 min, and
then extracted with phenol/chloroform. The cDNA products
were recovered by ethanol precipitation and dissolved in water
for PCR amplification.
PCR amplification was done from JE SA14-14-2 cDNA
using the Expand High Fidelity PCR System (Roche). Reaction
mixtures contained 10 pmol each of sense and antisense primers
and were run for 30 cycles with the following program after an
initial step of 94 °C for 2 min: 94 °C for 15 s, 60 °C for 30 s,
68 °C for 4 min. The final elongation step was at 72 °C for
10 min. The PCR product was isolated by agarose gels electro-
phoresis, visualized by crystal violet staining, excised and
recovered by addition of 3 volumes of 6 M sodium iodide and
incubation at 70 °C and purified with Wizard PCR Preps DNA
Purification System (Promega).
The plasmid pJE5′NK/5′CprME(S) was obtained by repla-
cing the sequence between the NotI site immediately upstream
of the SP6 promoter sequence and the MunI site (nt 2413 of the
JEV genome) of pJE5′NB25 with a corresponding fragment
generated from the JE SA14-14-2 PCR product described
above. The PCR fragment was digested with NotI and MunI
and ligated into pJE5′NB25 to produce pJE5′NK/5′CprME(S).
The sequence of the resulting plasmid was analyzed from the 5′
terminus through the E–NS1 junction.
The plasmid pJE5′NK/prME(S) was generated using a PCR
ligation strategy to exchange the fragment between the 5′ ter-
minus and the C/prM junction in pJE5′NK/5′CprME(S) with
sequence from JE Nakayama virus. Based on comparison of the
nucleotide sequences of the JE SA14-14-2 and JE Nakayama
viruses, there are no amino acid differences immediately up-stream of the C/prM junction. An overlapping DNA sequence
of 10 base pairs was used for the ligation of two PCR fragments
generated from JE Nakayama and JE SA14-14-2 viruses. The
JE Nakayama fragment from the 5′ terminus through the 3′
terminus of the capsid region was amplified from pJE5′NB25
using the primer JE5′-Sp6 and a second primer JE (C−): 5′-
GAAATTTGACAACTTCATGGCTCCTGCGCAG-3′. The
second PCR fragment from the 3′ terminus of the JE SA14-
14-2 capsid region through the NheI site (nt 1124) near the 5′
terminus of the E protein was amplified from the JE SA14-14-2
PCR product described above using the primers JE prM(+): 5′-
CGTCCTCGGTACTTCAACA-3′ and the primer JE 1148–
1125(−): 5′-TTCTGACCTCAGCAAGTTGGCTAG-3′. The
PCR products were purified and quantitated. 100 ng of each
PCR product were mixed and diluted 1:500 and 1.0 μl was used
in a 50-μl PCR reaction in the absence of primers. The program
was run as follows: 94 °C for 1 min, 60 °C for 1 min, and 72 °C
for 5 min, followed by addition of 10 pmol each of primers JE5′
Sp6 and JE 1125(−), and the reaction was continued for
25 cycles. The amplified PCR product was purified and the
sequence confirmed. The product was digested with NotI and
NheI and used to replace the corresponding fragment in pJE5′
NK/5′CprME(S) to yield pJE5′NK/prME(S). The final clone
was analyzed by nucleotide sequencing.
RNA transcription and transfection
Full-length cDNA templates for recovery of infectious
intertypic JE-XJN/SA14-14-2 viruses were assembled using a
two-plasmid system analogous to that used for the production
of JE Nakayama virus from the JE-XJN clone (Chambers et
al., 2006). Full-length transcription templates were made by
ligating the 3.4 kb 5′ fragments from either pJE5′NK/5′
CprME(S) or pJE5′NK/prME(S) after digestion with NotI and
BspEI, together with the 7.4 kb 3′ fragment from pCR-XL3′
BK2 after digestion with KpnI and BspEI. Digested fragments
were isolated on crystal violet agarose gels, purified and
quantitated by comparison to DNA molecular weight standards
by ethidium bromide staining. Approximately 3.0 μg of the
3.4 kb NotI/BspEI fragment and 12.0 μg of the 7.6 kb BspEI/
KpnI fragment were added to ligation reactions containing
400 units of T4 DNA ligase (NEB) for 12 h at 16 °C. The
ligation reactions were then heat inactivated, extracted with
phenol/chloroform and precipitated with ethanol. The final
pellet was dissolved in TE (10 mM Tris–HCl pH 7.5, 1 mm
EDTA), and the presence of full-length ligation product was
verified by agarose gel electrophoresis. In vitro-ligated tem-
plates were transcribed using SP6 polymerase (NEB), essen-
tially as described previously (Rice et al., 1989), Transfection
of confluent BHK cells was done using a mixture of 1/4 of the
in vitro-transcribed RNA, and 20 μg of Lipofectin (Gibco/
BRL) and phosphate-buffered saline in a volume of 300 μl
for 15 min at 37 °C, followed by washing the cells with
alpha-MEM plus 3% FBS. Cells were then incubated at 37 °C
in the same media. Media were harvested at onset of cytopa-
thic effects, between 4 and 5 days posttransfection, and infec-
tious virus was titrated by plaque assay on Vero cells. Viruses
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stocks.
Virus growth curves
Analysis of virus production in cell culture was done in
confluent monolayers of LLC-MK2 or C6/36 cells, using low
multiplicity infections for each virus tested (0.05 PFU/cell).
After initial infection for 1 h at 37 °C (LLC-MK2) or 28 °C (C6/
36 cells), media were replaced and cells were incubated at 37 °C
(LLC-MK2 cells) or 28 °C (C6/36 cells). Media were harvested
at approximately 12- or 24-h intervals followed by replacement
with fresh media (alpha MEM plus 5% FBS). Virus yields were
quantitated by plaque titration on Vero cells as described above.
Nucleotide sequence analyses
Plasmids encoding the intertypic JE Nakayama/JE SA14-14-
2 viruses were sequenced using Applied Biosystems Big Dye
sequence reactions and analyzed on an ABI sequencer. Viruses
were also sequenced by recovering RNA from virus-infected
cells and sequencing PCR products generated by RT–PCR of
the region from the 5′ terminus through the E/NS1 junction.
Molecular modelling
RNA structures were generated with RNAmfold, version 3.2
(Zuker et al., 1999; Mathews et al., 1999). Folding was deter-
mined for nucleotides 1–71 at 37 °C over a range of free
energies resulting from setting a suboptimality value of 30%, to
define the extent of variability of predicted structures for the 5′
UTRs of the JE-XJN, JE-X/5′CprME(S) and JE SA14-14-2
viruses.
A homology model for the JEV capsid protein based on the
NMR structure of the dimeric capsid protein of dengue-2 (PDB
ID code 1R6R) (Ma et al., 2004), was generated by the auto-
mated comparative protein modeling server Swiss-Model using
the first approach mode (Peitsch, 1995; Guex and Peitsch, 1997;
Schwede et al., 2003). Sequence alignment was determined by
Swiss-Model, which aligned amino acids 26 to 100 of the
dengue-2, JE Nakayama and JE SA14-14-2 capsid proteins.
Rotamers for amino acids at positions 40 and 66 were analyzed
for the most favorable energy configuration using calculation
provided by the modelling tools. Hydrogen bonds were deter-
mined by the Swiss-Pdb viewer.
Plaque reduction neutralization testing
Plaque reduction neutralization assay for JE virus was done
as described previously (Chambers et al., 2006). JE hyper-
immune ascitic fluid and control nonimmune ascitic fluids were
obtained from the ATCC. Approximately 100 PFU of input JE
Nakayama virus were mixed with serial 2-fold dilutions of
immune ascitic fluid, nonimmune control ascitic fluid, or test
sera in a standard experiment. The reaction mixture was kept at
4 °C for 6 h, followed by plaque assay on Vero cells using
conditions described above.Mouse experiments
ICR mice were purchased from Harlan Sprague Dawley
(Indianapolis, IN), and handled in accordance with a protocol
approved by the Institutional Committee on the Care and Use of
Laboratory Animals. Mice were used for immunization at 3–
5 weeks of age, and for neurovirulence testing at 4 weeks of age.
Immunized mice were challenged at 8 weeks post-immuniza-
tion, by inoculation with JE Nakayama virus. Mice were
observed for 4 weeks, or until moribund, and then euthanized, at
which time sera were collected for measurement of neutralizing
antibody titers. LD50 values were determined by the method of
Reed and Muench (1938).
Statistical analyses
Differences in mortality endpoints were analyzed using
Fisher's Exact Test. Differences in average survival times were
measured using log rank testing. Differences in neutralizing
antibody titers were determined with independent means t-tests
of log transformed data. Data calculations were performed with
the SPSS package.
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